These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 16397787)

  • 1. Successful treatment of lymph node extramedullary plasmacytoma with bortezomib.
    Pantelidou D; Tsatalas C; Margaritis D; Anastasiadis AG; Kaloutsi V; Argyropoulou P; Prassopoulos P; Bourikas G
    Ann Hematol; 2006 Mar; 85(3):188-90. PubMed ID: 16397787
    [No Abstract]   [Full Text] [Related]  

  • 2. Bortezomib in combination with thalidomide and dexamethasone--a successful treatment regimen in refractory extramedullary multiple myeloma.
    Dytfeld D; Matuszak M; Lewandowski K; Komarnicki M
    Ann Hematol; 2008 Mar; 87(3):253-4. PubMed ID: 17955241
    [No Abstract]   [Full Text] [Related]  

  • 3. Relapsed multiple myeloma presenting as an orbital plasmacytoma.
    Liao J; Greenberg A; Shinder R
    Ophthalmic Plast Reconstr Surg; 2011; 27(6):461. PubMed ID: 22072197
    [No Abstract]   [Full Text] [Related]  

  • 4. Bortezomib in treatment of extramedullary plasmacytoma of the pancreas.
    Wei JY; Tong HY; Zhu WF; Liu H; Zhang FJ; Yu WJ; Jin J
    Hepatobiliary Pancreat Dis Int; 2009 Jun; 8(3):329-31. PubMed ID: 19502179
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of Bortezomib followed by local irradiation in two patients with extramedullary plasmacytomas.
    Varettoni M; Mangiacavalli S; Zappasodi P; Pica GM; Lazzarino M; Corso A
    Leuk Res; 2008 May; 32(5):839-41. PubMed ID: 17997154
    [No Abstract]   [Full Text] [Related]  

  • 6. Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3.
    Barlogie B; Anaissie E; van Rhee F; Haessler J; Hollmig K; Pineda-Roman M; Cottler-Fox M; Mohiuddin A; Alsayed Y; Tricot G; Bolejack V; Zangari M; Epstein J; Petty N; Steward D; Jenkins B; Gurley J; Sullivan E; Crowley J; Shaughnessy JD
    Br J Haematol; 2007 Jul; 138(2):176-85. PubMed ID: 17593024
    [TBL] [Abstract][Full Text] [Related]  

  • 7. VAD combination chemotherapy followed by bortezomib may be an effective treatment in secondary plasma cell leukemia.
    Ataergin S; Arpaci F; Kaya A; Cetin T; Gunhan O
    Am J Hematol; 2006 Dec; 81(12):987-8. PubMed ID: 16888783
    [No Abstract]   [Full Text] [Related]  

  • 8. Myeloma presenting during pregnancy.
    Smith D; Stevens J; Quinn J; Cavenagh J; Ingram W; Yong K
    Hematol Oncol; 2014 Mar; 32(1):52-5. PubMed ID: 23996410
    [No Abstract]   [Full Text] [Related]  

  • 9. Bortezomib in relapsed multiple myeloma complicated by extramedullary plasmacytomas.
    Hughes M; Micallef-Eynaud P
    Clin Lab Haematol; 2006 Aug; 28(4):267-9. PubMed ID: 16898968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem cell transplantation for multiple myeloma.
    Eom HS; Min CK; Cho BS; Lee S; Lee JW; Min WS; Kim CC; Kim M; Kim Y
    Jpn J Clin Oncol; 2009 Jul; 39(7):449-55. PubMed ID: 19487425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful treatment of early relapse of ocular myeloma with bortezomib and steroid after autologous stem cell transplantation.
    Yavasoglu I; Kocaturk T; Kadikoylu G; Dayanir V; Dayanir Y; Bolaman Z
    Bratisl Lek Listy; 2010; 111(12):670-2. PubMed ID: 21384738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bortezomib and restoration of chemosensitivity.
    Gozzetti A
    Nat Rev Clin Oncol; 2009 Nov; 6(11):15-c1; author reply 15-c2. PubMed ID: 19877369
    [No Abstract]   [Full Text] [Related]  

  • 13. Bortezomib: 3 deaths following intrathecal injection.
    Prescrire Int; 2012 Sep; 21(130):214. PubMed ID: 23016258
    [No Abstract]   [Full Text] [Related]  

  • 14. Treatment of multiple myeloma: 2009 update.
    Prescrire Int; 2009 Dec; 18(104):263-6. PubMed ID: 20025098
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial.
    Harousseau JL; Attal M; Avet-Loiseau H; Marit G; Caillot D; Mohty M; Lenain P; Hulin C; Facon T; Casassus P; Michallet M; Maisonneuve H; Benboubker L; Maloisel F; Petillon MO; Webb I; Mathiot C; Moreau P
    J Clin Oncol; 2010 Oct; 28(30):4621-9. PubMed ID: 20823406
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autologous stem cell transplant for light chain deposition disease: incorporating bortezomib to the induction therapy.
    Jimenez-Zepeda VH; Trudel S; Winter A; Reece DE; Chen C; Kukreti V
    Am J Hematol; 2012 Aug; 87(8):822-3. PubMed ID: 22641434
    [No Abstract]   [Full Text] [Related]  

  • 17. Central nervous system involvement with multiple myeloma: long term survival can be achieved with radiation, intrathecal chemotherapy, and immunomodulatory agents.
    Chen CI; Masih-Khan E; Jiang H; Rabea A; Cserti-Gazdewich C; Jimenez-Zepeda VH; Chu CM; Kukreti V; Trudel S; Tiedemann R; Tsang R; Reece DE
    Br J Haematol; 2013 Aug; 162(4):483-8. PubMed ID: 23772701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Progressive hypertelorism secondary to craniofacial plasmocytoma].
    De Lucas G; Arias F; Redondo F; De Bonis M
    Acta Otorrinolaringol Esp; 2011; 62(4):327-8. PubMed ID: 20394910
    [No Abstract]   [Full Text] [Related]  

  • 19. [Development of an extramedullary plasmacytoma despite disappearing M protein in multiple myeloma by bortezomib treatment].
    Koiso H; Tahara K; Osaki Y; Mawatari M; Sekigami T; Yokohama A; Saitoh T; Uchiumi H; Handa H; Tsukamoto N; Karasawa M; Nojima Y; Murakami H
    Rinsho Ketsueki; 2009 Feb; 50(2):78-82. PubMed ID: 19265298
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effective combination therapy of bortezomib and dexamethasone for a plasma cell leukemia patient with multiple osteolytic lesions and extramedullary involvement.
    Capalbo S; Chiefa A; Delia M; Diomede D; Liso V
    Acta Oncol; 2007; 46(2):262-4. PubMed ID: 17453381
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.